Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

COSENTYX

SECUKINUMAB

Standard Dose
150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview COSENTYX is listed in Drugs@FDA under application 761349 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SECUKINUMAB Form and strength INJECTABLE;INJECTION - 150MG Sponsor NOVARTIS PHARMS CORP Submission history Latest submission status date: 2026-03-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview COSENTYX is listed in Drugs@FDA under application 761349 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient SECUKINUMAB Form and strength INJECTABLE;INJECTION - 150MG Sponsor NOVARTIS PHARMS CORP Submission history Latest submission status date: 2026-03-12 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.